Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6500
-0.0050 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
0.6590
+0.0090 (1.38%)
After-hours: Dec 5, 2025, 7:59 PM EST
Plus Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 13.29 | 0.08 | 8.55 | 18.12 | 18.4 | 8.35 | Upgrade
|
| Short-Term Investments | 3.31 | 3.53 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 16.6 | 3.61 | 8.55 | 18.12 | 18.4 | 8.35 | Upgrade
|
| Cash Growth | 246.72% | -57.84% | -52.79% | -1.52% | 120.47% | -52.45% | Upgrade
|
| Accounts Receivable | - | 0.57 | - | - | - | - | Upgrade
|
| Receivables | - | 0.57 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 0.69 | 0.65 | 1.05 | 3.7 | 1.32 | 0.77 | Upgrade
|
| Other Current Assets | 0.3 | 0.44 | 0.23 | - | 0.01 | 0.06 | Upgrade
|
| Total Current Assets | 17.59 | 5.26 | 9.83 | 21.82 | 19.72 | 9.18 | Upgrade
|
| Property, Plant & Equipment | 0.29 | 0.52 | 1.11 | 1.57 | 1.82 | 2.46 | Upgrade
|
| Goodwill | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | Upgrade
|
| Other Intangible Assets | 0.37 | 0.47 | 0.04 | 0.09 | 0.05 | 0.09 | Upgrade
|
| Other Long-Term Assets | 0.05 | 0.01 | 0.03 | 0.01 | 0.02 | 0.02 | Upgrade
|
| Total Assets | 18.67 | 6.63 | 11.39 | 23.87 | 21.98 | 12.11 | Upgrade
|
| Accounts Payable | 5.22 | 9.47 | 4.76 | 8.36 | 2.61 | 0.79 | Upgrade
|
| Accrued Expenses | - | 1.81 | 1.87 | 1.77 | 1.42 | 1.26 | Upgrade
|
| Short-Term Debt | 6.4 | 3.29 | - | - | - | - | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 3.98 | 1.61 | 1.61 | 6.34 | Upgrade
|
| Current Portion of Leases | 0.02 | 0.04 | 0.12 | 0.11 | 0.11 | 0.13 | Upgrade
|
| Current Unearned Revenue | 1.97 | 0.93 | - | - | - | - | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.12 | 0.02 | Upgrade
|
| Total Current Liabilities | 13.62 | 15.55 | 10.73 | 11.85 | 5.87 | 8.54 | Upgrade
|
| Long-Term Debt | - | - | - | 3.79 | 5.01 | - | Upgrade
|
| Long-Term Leases | - | 0.03 | 0.09 | 0.14 | 0.27 | 0.53 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 1.92 | 1.64 | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0 | 0.01 | Upgrade
|
| Total Liabilities | 13.62 | 15.58 | 12.74 | 17.42 | 11.15 | 9.07 | Upgrade
|
| Common Stock | 0.13 | 0.01 | 0.01 | 0 | 0.02 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 515.57 | 485.02 | 479.27 | 473.63 | 457.73 | 436.54 | Upgrade
|
| Retained Earnings | -510.15 | -493.48 | -480.5 | -467.19 | -446.91 | -433.51 | Upgrade
|
| Treasury Stock | -0.5 | -0.5 | -0.13 | - | - | - | Upgrade
|
| Shareholders' Equity | 5.05 | -8.95 | -1.35 | 6.45 | 10.84 | 3.03 | Upgrade
|
| Total Liabilities & Equity | 18.67 | 6.63 | 11.39 | 23.87 | 21.98 | 12.11 | Upgrade
|
| Total Debt | 6.42 | 3.37 | 4.18 | 5.65 | 6.99 | 7 | Upgrade
|
| Net Cash (Debt) | 10.18 | 0.24 | 4.37 | 12.48 | 11.41 | 1.35 | Upgrade
|
| Net Cash Growth | 633.43% | -94.53% | -64.95% | 9.36% | 744.96% | -75.77% | Upgrade
|
| Net Cash Per Share | 0.22 | 0.03 | 1.39 | 7.13 | 14.15 | 4.57 | Upgrade
|
| Filing Date Shares Outstanding | 137.43 | 17 | 4.28 | 2.34 | 1.48 | 0.45 | Upgrade
|
| Total Common Shares Outstanding | 131.61 | 5.9 | 4.44 | 2.24 | 1.03 | 0.45 | Upgrade
|
| Working Capital | 3.97 | -10.29 | -0.89 | 9.97 | 13.85 | 0.64 | Upgrade
|
| Book Value Per Share | 0.04 | -1.52 | -0.30 | 2.88 | 10.48 | 6.74 | Upgrade
|
| Tangible Book Value | 4.31 | -9.79 | -1.76 | 5.98 | 10.41 | 2.57 | Upgrade
|
| Tangible Book Value Per Share | 0.03 | -1.66 | -0.40 | 2.67 | 10.07 | 5.72 | Upgrade
|
| Machinery | - | 1.78 | 1.63 | 1.47 | 1.23 | 1.53 | Upgrade
|
| Leasehold Improvements | - | 1.81 | 1.81 | 1.81 | 1.66 | 1.68 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.